Truenat HR-HPV-Plus, made by Goa-based Molbio Diagnostics, is the first indigenous point-of-care HPV test to meet international (IARC) validation criteria for cervical cancer screening.
The study by AIIMS New Delhi, two ICMR institutes and WHO's International Agency for Research on Cancer was published in the International Journal of Cancer in June 2026.
Four point-of-care HPV assays were tested on 1,159 cervical samples from the ESTAMPA study in Argentina and Costa Rica; Truenat met every criterion.
The test detects eight high-risk HPV types that account for about 95% of cervical cancers, and runs on the battery-operated Truenat platform already used for TB.
The work was funded by DBT-BIRAC under Grand Challenges India.
Cervical cancer is caused by persistent infection with high-risk human papillomavirus. A DNA test finds the virus before cells turn cancerous. A reduced-valency assay looks for only the most cancer-causing types, which cuts false alarms and cost.
Simple Analogy: Like a metal detector tuned only for weapons, so that keys and coins stop triggering it.
WHO's specialised cancer research agency, set up in 1965; its criteria are the international standard for validating HPV screening tests.
Apex biomedical research body, founded in 1911 as the Indian Research Fund Association and renamed in 1949; under the Department of Health Research.
Not-for-profit public sector enterprise set up in 2012 by the Department of Biotechnology; runs Grand Challenges India.
Maker of the Truenat chip-based real-time PCR platform, which WHO endorsed for tuberculosis testing in 2020.
Protect girls before exposure to HPV.
Key: Launched by the Prime Minister at Ajmer, Rajasthan, on 28 February 2026; a free single dose of Gardasil-4 for about 1.15 crore girls aged 14 each year.
Bring incidence below 4 per 1,00,000 women.
Key: 90-70-90 targets for 2030: 90% of girls vaccinated by age 15, 70% of women screened with a high-performance test by 35 and again by 45, 90% of women with disease treated.
India's first indigenous quadrivalent HPV vaccine.
Key: Developed by the Serum Institute of India with DBT-BIRAC support.
GS Paper 3 > Science and Technology > Indigenisation of technology; GS Paper 2 > Health
General Awareness > Science and health in news
General Awareness > Current events
Human papillomavirus; types 16 and 18 together cause about 70% of cervical cancers.
Cervical intraepithelial neoplasia grade 2 or worse, the precancer threshold used to judge a screening test.
A test run near the patient, without a central laboratory.
An HPV test that targets only the 7-8 most carcinogenic types instead of 14.